source
- AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight lossAstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
- Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug developmentParabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…